Cargando…
Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia sympt...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193732/ https://www.ncbi.nlm.nih.gov/pubmed/34122009 http://dx.doi.org/10.3389/fnmol.2021.673144 |
_version_ | 1783706287046918144 |
---|---|
author | Falvella, Ana Caroline Brambilla Smith, Bradley Joseph Silva-Costa, Licia C. Valença, Aline G. F. Crunfli, Fernanda Zuardi, Antonio W. Hallak, Jaime E. Crippa, José A. de Almeida, Valéria Martins-de-Souza, Daniel |
author_facet | Falvella, Ana Caroline Brambilla Smith, Bradley Joseph Silva-Costa, Licia C. Valença, Aline G. F. Crunfli, Fernanda Zuardi, Antonio W. Hallak, Jaime E. Crippa, José A. de Almeida, Valéria Martins-de-Souza, Daniel |
author_sort | Falvella, Ana Caroline Brambilla |
collection | PubMed |
description | Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia symptoms. While oligodendrocytes are known to be relevant targets of antipsychotics, the biochemical knowledge in this regard is still limited. Here we evaluated the molecular pathways modulated by cannabidiol compared to the antipsychotics clozapine (atypical) and haloperidol (typical), additionally evaluating the effects of benztropine, a muscarinic receptor antagonist that displays a protective effect in oligodendrocytes and myelination. For this purpose, we employed nano-chromatography coupled with mass spectrometry to investigate the proteomic response to these drugs both in healthy oligodendrocytic cells and in a cuprizone-based toxicity model, using the human oligodendrocyte precursor cell line MO3.13. Cannabidiol shares similarities of biochemical pathways with clozapine and benztropine, in agreement with other studies that indicated an atypical antipsychotic profile. All drugs tested affected metabolic and gene expression pathways and cannabidiol, benztropine, and clozapine modulated cell proliferation and apoptosis when administered after cuprizone-induced toxicity. These general pathways are associated with cuprizone-induced cytotoxicity in MO3.13 cells, indicating a possible proteomic approach when acting against the toxic effects of cuprizone. In conclusion, although modeling oligodendrocytic cytotoxicity with cuprizone does not represent the entirety of the pathophysiology of oligodendrocyte impairments, these results provide insight into the mechanisms associated with the effects of cannabidiol and antipsychotics against cuprizone toxicity, offering new directions of study for myelin-related processes and deficits. |
format | Online Article Text |
id | pubmed-8193732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81937322021-06-12 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 Falvella, Ana Caroline Brambilla Smith, Bradley Joseph Silva-Costa, Licia C. Valença, Aline G. F. Crunfli, Fernanda Zuardi, Antonio W. Hallak, Jaime E. Crippa, José A. de Almeida, Valéria Martins-de-Souza, Daniel Front Mol Neurosci Molecular Neuroscience Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia symptoms. While oligodendrocytes are known to be relevant targets of antipsychotics, the biochemical knowledge in this regard is still limited. Here we evaluated the molecular pathways modulated by cannabidiol compared to the antipsychotics clozapine (atypical) and haloperidol (typical), additionally evaluating the effects of benztropine, a muscarinic receptor antagonist that displays a protective effect in oligodendrocytes and myelination. For this purpose, we employed nano-chromatography coupled with mass spectrometry to investigate the proteomic response to these drugs both in healthy oligodendrocytic cells and in a cuprizone-based toxicity model, using the human oligodendrocyte precursor cell line MO3.13. Cannabidiol shares similarities of biochemical pathways with clozapine and benztropine, in agreement with other studies that indicated an atypical antipsychotic profile. All drugs tested affected metabolic and gene expression pathways and cannabidiol, benztropine, and clozapine modulated cell proliferation and apoptosis when administered after cuprizone-induced toxicity. These general pathways are associated with cuprizone-induced cytotoxicity in MO3.13 cells, indicating a possible proteomic approach when acting against the toxic effects of cuprizone. In conclusion, although modeling oligodendrocytic cytotoxicity with cuprizone does not represent the entirety of the pathophysiology of oligodendrocyte impairments, these results provide insight into the mechanisms associated with the effects of cannabidiol and antipsychotics against cuprizone toxicity, offering new directions of study for myelin-related processes and deficits. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8193732/ /pubmed/34122009 http://dx.doi.org/10.3389/fnmol.2021.673144 Text en Copyright © 2021 Falvella, Smith, Silva-Costa, Valença, Crunfli, Zuardi, Hallak, Crippa, Almeida and Martins-de-Souza. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Neuroscience Falvella, Ana Caroline Brambilla Smith, Bradley Joseph Silva-Costa, Licia C. Valença, Aline G. F. Crunfli, Fernanda Zuardi, Antonio W. Hallak, Jaime E. Crippa, José A. de Almeida, Valéria Martins-de-Souza, Daniel Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title | Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title_full | Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title_fullStr | Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title_full_unstemmed | Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title_short | Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 |
title_sort | cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line mo3.13 |
topic | Molecular Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193732/ https://www.ncbi.nlm.nih.gov/pubmed/34122009 http://dx.doi.org/10.3389/fnmol.2021.673144 |
work_keys_str_mv | AT falvellaanacarolinebrambilla cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT smithbradleyjoseph cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT silvacostaliciac cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT valencaalinegf cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT crunflifernanda cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT zuardiantoniow cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT hallakjaimee cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT crippajosea cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT dealmeidavaleria cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 AT martinsdesouzadaniel cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313 |